VERA Vera Therapeutics Inc - Ordinary Shares - Class A

$VERA -70% underperformance YTD compared to XBI. Serious games here, volume low - this is when I think about a starter.

$VERA So apparently people were selling the stock today because the event risk reductions that were reported by of 76% was lower than Otsuka's 97% (and ignoring that their hematuria rates were better). Except the people selling failed to realize the two values had different methodologies and when you adjust for them, they look essentially equivalent. Does no one do any actual work anymore? Or is it just "A less than B, sell sell sell"? What's the point of hiring all these overly-educated analysts if your analytical effectiveness is equivalent to a boiled potato?

$VERA Bids on Puts Oct - Dec 25 and below virtually non-existent. Maybe this means something. Hopefully we are nearing a short-term bottom... I do hope

$VERA Yesterday I bot the March 35/40 call debit spread for .95. Seems like a good trade.

$VERA Fishiest price action in all of quality bio right now. Green candles, strange red to green moves, high volume.

$VERA This probably rallies after October options exp in anticipation of "Kidney Week" presentations. (At least I am hoping so.)

$VERA Not that I follow the analyst, but the avg analyst PTs are in the 70s. And, this is below 30 with Institutionals owning most of the shares.

$VERA instead of posting stupid animes on LinkedIn and reiterating the same old date drop the p2 news from Sunday and start some proper pr.

$VERA a $2 dividend would cost shorty $34.5M and would get us out of a rut. Would be a good use of $144 mil of company coffers. They know most of us will reinvest, esp hedgies. I just want to see it at fair value and let the launch dictate the rest. This short bs is ridiculous.

$VERA Watching here. Short the launch games. Can end soon, can go on for a very long time.

$VERA atest October 2026 updates, with strong bullish catalysts driven by TRUTAKNA’s Phase III success and upcoming regulatory milestones. Analyst Ratings (October 2026) Raymond James: Strong Buy, $84 PT. Cantor Fitzgerald: Overweight, $100 PT. BofA Securities: Buy, $60 PT (revised). Leerink Partners: Market Perform, $34 PT. Consensus PT: ~$80.15.

Textbook biotech week. $VERA lands an FDA approval for Trutakna in IgA nephropathy on real Phase 3 data and the stock still cannot catch a bid. Down roughly 43 percent this year with an approval in hand. When the sector is this heavy, good news is just liquidity for sellers. That is the tape we are in.

📅 CATALYST REMINDER | $VERA October 22 & 24, 2026 — Clinical Data Presentations October 22: atacicept ORIGIN 3 final efficacy analysis. October 24: interim Phase 2 PIONEER findings. Both are scheduled for ASN Kidney Week. More details in our hub. #VERA #Biotech #ClinicalData

$VERA is this an indication share price is bound for a rebound towards $35. Am I reading this correctly?

$VERA correction, only 4M+ shares, sleepy when doing the arithmetic😄 Though, that many shares covered between 10/1 and 10/15, price had never moved😂 That’s how rigged it is!🤬

$VERA Vera therapeutics announces origin 3 final efficacy analysis of trutakna™ (atacicept-vymj) in iga nephropathy will be a featured late-breaking oral presentation at the opening plenary session of asn kidney week 2026